DE3310079C2 - - Google Patents

Info

Publication number
DE3310079C2
DE3310079C2 DE3310079A DE3310079A DE3310079C2 DE 3310079 C2 DE3310079 C2 DE 3310079C2 DE 3310079 A DE3310079 A DE 3310079A DE 3310079 A DE3310079 A DE 3310079A DE 3310079 C2 DE3310079 C2 DE 3310079C2
Authority
DE
Germany
Prior art keywords
eye
ophthalmic
compounds
cornea
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3310079A
Other languages
German (de)
English (en)
Other versions
DE3310079A1 (de
Inventor
David Lowell San Mateo Calif. Us Waterbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of DE3310079A1 publication Critical patent/DE3310079A1/de
Application granted granted Critical
Publication of DE3310079C2 publication Critical patent/DE3310079C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE19833310079 1982-03-22 1983-03-21 Topische ophthalmische arzneimittel Granted DE3310079A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/360,754 US4454151A (en) 1982-03-22 1982-03-22 Use of pyrrolo pyrroles in treatment of ophthalmic diseases

Publications (2)

Publication Number Publication Date
DE3310079A1 DE3310079A1 (de) 1983-09-22
DE3310079C2 true DE3310079C2 (enExample) 1990-10-18

Family

ID=23419287

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19833310079 Granted DE3310079A1 (de) 1982-03-22 1983-03-21 Topische ophthalmische arzneimittel

Country Status (6)

Country Link
US (1) US4454151A (enExample)
JP (1) JPS58172314A (enExample)
AU (1) AU568072B2 (enExample)
DE (1) DE3310079A1 (enExample)
IT (1) IT1162842B (enExample)
NZ (1) NZ203639A (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4826869A (en) * 1988-02-19 1989-05-02 Syntex (U.S.A.) Inc. N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5271939A (en) * 1988-10-03 1993-12-21 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US4939135A (en) * 1988-10-03 1990-07-03 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
US5422073A (en) * 1990-12-27 1995-06-06 Allergan, Inc. Method and composition for disinfecting contact lenses
US5207660A (en) * 1991-04-26 1993-05-04 Cornell Research Foundation, Inc. Method for the delivery of compositions to the ocular tissues
EP0612521B1 (en) * 1991-11-11 1999-06-30 Hisamitsu Pharmaceutical Co., Inc. Fomentation containing ketorolac
AU5450494A (en) * 1992-10-30 1994-05-24 Syntex (U.S.A.) Inc. Transdermal delivery of ketorolac
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
WO1995001767A1 (en) * 1993-07-08 1995-01-19 Cygnus Therapeutic Systems Monolithic matrix transdermal delivery system
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US6191285B1 (en) 1997-07-03 2001-02-20 Abbott Laboratories Process for the preparation of ketorolac tromethamine
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
PT1380302E (pt) * 2001-03-28 2008-11-25 Santen Pharmaceutical Co Ltd Medicamentos para doenças da retina e coróide que contêm esteróides como ingrediente activo
AU2002247284A1 (en) 2001-04-02 2002-10-15 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2468664C (en) * 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
EP1824496A4 (en) * 2004-11-17 2008-07-16 Joanne Mclaurin COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
WO2007041855A1 (en) * 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070197453A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
CN103054837A (zh) * 2006-03-09 2013-04-24 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
CA2650592A1 (en) * 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
WO2008061373A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and similar diseases
BRPI0808410A2 (pt) * 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
CA2683546A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
CA2683580A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
JP2010523602A (ja) 2007-04-12 2010-07-15 ワラタ ファーマシューティカルズ， インコーポレイテッド 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用
WO2008124930A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
WO2008153746A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
RU2359658C1 (ru) * 2008-02-22 2009-06-27 Ирина Александровна Глущенко Средство для профилактики и лечения офтальмологических заболеваний
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
CA2740124A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US8778999B2 (en) 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
CN105188733B (zh) 2013-03-13 2020-05-08 建新公司 包含pdgf和vegf结合部分的融合蛋白及其使用方法
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
KR20260039752A (ko) 2023-07-13 2026-03-20 크리야 테라퓨틱스, 인크. 보체 경로 억제제 융합체 및 그의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4087539A (en) * 1976-07-14 1978-05-02 Syntex (U.S.A.) Inc. 5-(2-Furoyl)-, 5-(2-thenoyl)-, 5-(3-furoyl)- and 5-(3-thenoyl)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4097579A (en) * 1977-03-31 1978-06-27 Syntex (U.S.A.) Inc. 5-(2-Pyrroyl)-1,2-dihydro-3H-pyrrolo 1,2-a!pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4140698A (en) * 1977-07-25 1979-02-20 Syntex (Usa) Inc. 1,2-Dihydro-3H-pyrrolo[1,2-a]pyrrole-1-nitriles
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
US4344943A (en) * 1980-06-09 1982-08-17 Syntex (U.S.A.) Inc. 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof

Also Published As

Publication number Publication date
JPH047324B2 (enExample) 1992-02-10
AU568072B2 (en) 1987-12-17
IT8367315A0 (it) 1983-03-21
JPS58172314A (ja) 1983-10-11
IT1162842B (it) 1987-04-01
NZ203639A (en) 1988-05-30
AU1265183A (en) 1983-09-29
US4454151A (en) 1984-06-12
DE3310079A1 (de) 1983-09-22

Similar Documents

Publication Publication Date Title
DE3310079C2 (enExample)
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
US4452818A (en) Extraocular method of treating the eye with liquid perfluorocarbons
DE69630325T2 (de) Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
DE69326610T2 (de) Arzneimittel gegen glaukom
JPH01104023A (ja) 眼用保存製剤およびその製法
JP2023550632A5 (enExample)
DE69208941T2 (de) Augenpräparate mit verlängerter Freigabe
JPH04221322A (ja) 眼病用製剤
DE69721824T2 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
DE60013126T2 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
EP0585896B1 (de) Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US4459309A (en) Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye
DE69921678T2 (de) Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen
EP0410749B1 (en) Anthocyanidins for the treatment of ophthalmic diseases
DE69227324T2 (de) Pharmazeutische zusammensetzung, die carbachol und andere cholinerge substanzen enthält
DE10360425A1 (de) Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
DE3688503T2 (de) Erhöhung des ausfliessens wässriger körperfluessigkeit.
DE60213230T2 (de) Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
US4477460A (en) Topical treatment of ocular hypertension
ELLIS et al. Comparative intraocular levels of pilocarpine achieved with drops and repository preparations
CA2929965C (en) Method and composition for treating glaucoma
US20240299291A1 (en) Ophthalmic preparation administered by eye drops and used for preventing and treating dry macular degeneration and retinal light damage
DE69113675T2 (de) Verwendung von Naproxen als Mydriatikum.
de ROETTH Ophthalmic pharmacology and toxicology

Legal Events

Date Code Title Description
8101 Request for examination as to novelty
8105 Search report available
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN